Rydex Biotechnology A RYBOX
Set alert
81.22 USD -0.09 -0.11%
At close · Oct 30
Day range unavailable
59.34 52-week range 81.31
- YTD
- +31.59%
- 1 year
- +21.61%
- Open
- —
- Prev close
- 81.31
- Mkt cap
- 0
- Vol
- 0
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- —
- High
- —
- Forward P/E
- 0.00
- Beta
- 0.00
- Short ratio
- 0.00
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 66.77
- 200-d avg
- 66.24
3M chart
Signals (24)
| Name | Date | Ago |
|---|---|---|
| SMA: Bullish | Oct 20, 2026 | 1 week ago |
| SMA: Bullish | Oct 20, 2026 | 1 week ago |
| MACD: Buy Signal | Oct 20, 2026 | 1 week ago |
| SMA: Bearish | Oct 16, 2026 | 2 weeks ago |
| SMA: Bearish | Oct 16, 2026 | 2 weeks ago |
| SMA: Bullish | Oct 15, 2026 | 2 weeks ago |
| SMA: Bullish | Oct 15, 2026 | 2 weeks ago |
| SMA: Bearish | Oct 12, 2026 | 2 weeks ago |
| SMA: Bullish | Oct 9, 2026 | 3 weeks ago |
| SMA: Bearish | Oct 6, 2026 | 3 weeks ago |
| SMA: Bearish | Sep 30, 2026 | 1 month ago |
| SMA: Bullish | Sep 24, 2026 | 1 month ago |
| SMA: Bearish | Sep 23, 2026 | 1 month ago |
| SMA: Bullish | Sep 21, 2026 | 1 month ago |
| SMA: Bearish | Sep 18, 2026 | 1 month ago |
| SMA: Bullish | Sep 17, 2026 | 1 month ago |
| SMA: Bearish | Sep 15, 2026 | 1 month ago |
| SMA: Bullish | Sep 14, 2026 | 1 month ago |
| SMA: Bearish | Sep 10, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 1, 2026 | 2 months ago |
| RSI: Overbought | Aug 19, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 10, 2026 | 2 months ago |
| SMA: Bullish | Aug 7, 2026 | 2 months ago |
| SMA: Bearish | Jul 31, 2026 | 3 months ago |
Key statistics
- Market cap
- 0
- Enterprise value
- 0
- Trailing P/E
- 0.00
- Forward P/E
- 0.00
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- EPS (TTM)
- 0.00
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Shares outstanding
- 0
- Short % of float
- 0.00%
- 50-day average
- 66.77
- 200-day average
- 66.24
About Rydex Biotechnology A
Under normal circumstances, the fund invests substantially all (at least 80%) of its net assets in equity securities of Biotechnology Companies that are traded in the United States and in derivatives, which primarily consist of futures contracts and options on securities, futures contracts, and stock indices. It may invest to a significant extent in the securities of Biotechnology Companies that have small to mid-sized capitalizations. The fund is non-diversified.
News
No recent headlines
Headlines appear here as they are published.
Your note
Sign in to keep a note on RYBOX — it syncs with the Stock Master app.